Long Acting Treatments for HIV and HIV-Associated Co-Infections (R61/R33 Clinical Trial Not Allowed)
The summary for the Long Acting Treatments for HIV and HIV-Associated Co-Infections (R61/R33 Clinical Trial Not Allowed) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Long Acting Treatments for HIV and HIV-Associated Co-Infections (R61/R33 Clinical Trial Not Allowed): The purpose of this Funding Opportunity is to stimulate new and innovative multidisciplinary research in the area of long acting therapeutics for HIV and HIV-associated tuberculosis (TB) and viral hepatitis B and C. Applications are sought that lead to new effective therapies for administration once per month or less frequently as oral, injectable, implantable, or transdermal products.
| Federal Grant Title: | Long Acting Treatments for HIV and HIV-Associated Co-Infections (R61/R33 Clinical Trial Not Allowed) |
| Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
| Grant Categories: | Health |
| Type of Opportunity: | Discretionary |
| Funding Opportunity Number: | RFA-AI-20-024 |
| Type of Funding: | Grant |
| CFDA Numbers: | 93.855 |
| CFDA Descriptions: | Information not provided |
| Current Application Deadline: | July 28th, 2020 |
| Original Application Deadline: | July 28th, 2020 |
| Posted Date: | March 23rd, 2020 |
| Creation Date: | March 23rd, 2020 |
| Archive Date: | September 2nd, 2020 |
| Total Program Funding: | $3,500,000 |
| Maximum Federal Grant Award: | |
| Minimum Federal Grant Award: | |
| Expected Number of Awards: | |
| Cost Sharing or Matching: | No |
| Last Updated: | March 23rd, 2020 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-024.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Immune Tolerance Network (UM1 Clinical Trial Required)
- • Accelerating Research and Development of Next Generation Vaccines against Malaria - a Mode...
- • Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)
- • Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- • Atopic Dermatitis Research Network (ADRN) (U19 Clinical Trial Optional)
- • Center for HIV/AIDS Vaccine Immunology (CHAVI)
- • Genomics of Transplantation Cooperative Research Program
- • Asthma and Allergic Diseases Cooperative Research Centers
- More Grants from the National Institutes of Health
- • Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinic...
- • Immune Tolerance Network (UM1 Clinical Trial Required)
- • Coordinating Center for National Resource Network for the Study of Human Auditory and Vest...
- • National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Cl...
- • Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Interven...